TL;DR
Solana Company, formerly known as Helius Medical Technologies, has made its resale registration effective, enabling early investors to sell their restricted shares on the open market.
The company said it decided to move forward as planned because it wants to accelerate market adjustment and achieve a more transparent valuation for its stock, HSDT.
The resale registration allows public trading of shares acquired during the most recent private placement. Solana Company believes that the initial price pressure will help flush out speculative capital and strengthen the base of committed long-term shareholders.
Executive Chairman Joseph Chee stated that it is better to absorb short-term pressure now and establish lasting market equilibrium. In his words, the company prefers to “rip off the bandage” rather than prolong instability.
The broader goal is to build the “Berkshire Hathaway of the Solana ecosystem.” The company wants to turn HSDT into a vehicle capable of actively accumulating SOL, generating steady returns through institutional-grade staking, and using capital markets to expand its holdings during volatile periods. It claims its structure will allow it to acquire more SOL per share than any individual investor and achieve yields above 7% annually.
With the registration now effective, HSDT will rank among the largest SOL DATs by effective market capitalization — a position that could attract institutional investors seeking direct exposure to SOL. Chee emphasized that if the stock trades below its net asset value, investors would essentially be “buying one dollar of Solana for less than a dollar.”
HSDT currently trades around $6.81. Solana Company also confirmed new partnerships with Coinbase, BitGo, and Anchorage Digital to manage custody of its SOL treasury
Also read: Cardano Faces Decline as Bulls Eye $0.75 Resistance for Recovery
